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ABSTRACT
Statins are frequently prescribed in clinical practice for their proven 
efficacy in prevention of cardiovascular and cerebrovascular disea-
ses. Despite the recognized beneficial effects of this class of drugs, 
in recent years, many studies published in medical literature have 
shown a wide range of adverse effects as a consequence of this the-
rapy, including the risk of peripheral neuropathy. The purpose of this 
article is to report a case in which clinical features consistent with 
multiple mononeuropathy probably secondary to use of pravastatin 
were observed. The case report is followed by a review of the relevant 
literature. 
Keywords: Multiple Mononeuropathy; Peripheral Neuropathy; Sta-
tins; Pravastatin 
RESUMO
As estatinas são frequentemente prescritas na prática clínica por sua 
comprovada eficácia na prevenção de doenças cardiovasculares e 
cérebrovasculares. Apesar dos reconhecidos efeitos benéficos dessa 
classe medicamentosa, nos últimos anos, diversos estudos publica-
dos na literatura médica vem evidenciando uma ampla variedade de 
efeitos colaterais como consequência desta terapia, incluindo o risco 
de neuropatias periféricas. O objetivo deste artigo é relatar um caso 
no qual foram observadas manifestações clínicas compatíveis com 
o diagnóstico de mononeuropatia múltipla sensitiva, provavelmente 
secundária ao uso de pravastatina. O relato de caso é acompanhan-
do de uma revisão de dados pertinentes da literatura.
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INTRODUCTION
Statins are hypolipidemic drugs widely prescribed 
in current clinical practice for their proven efficacy in pre-
vention of cerebrovascular and cardiovascular diseases, 
however, some complications may occur in association 
with long term use1. When considering the wide range of 
adverse effects secondary to this therapy, statin induced 
myopathy is recognized as a prevalent condition2, but oth-
er less frequent neuromuscular disorders have been de-
scribed in medical literature. Recently, growing evidence 
have pointed to the probable existence of peripheral neu-
ropathy secondary to certain drug-induced biochemical 
changes due to the inhibitory effect of 3-hydroxy-3-meth-
ylglutaryl coenzyme-A reductase (HMG-CoA Reductase)3, 
4, 5, 6. We report a case of a peripheral neuropathy probably 
induced by pravastatin use.
CASE REPORT
A 54-year-old male hypertense and dyslipidem-
ic patient in use of pravastatin 20mg/day for around two 
years reported, 30-days prior the consultation, insidious 
onset of paresthesia of the tingling type in the lateral region 
of his right foot. The symptoms exhibited a continuous and 
non-progressive pattern and were not associated with mo-
tor deficit, ataxia signs or dysautonomia. No worsening 
or improving factors were evident. After two weeks, he 
reported the onset, again insidious, of a similar complaint 
in the lateral part of the left foot, without irradiation. In 
this period, no fever, asthenia, weight loss, trauma, cutane-
ous lesions, joint problems or respiratory complaints were 
reported. There was no family history of similar clinical 
conditions. The general clinical exam was unremarkable. 
Objective neurological exam revealed preserved strength, 
globally symmetrical and physiological osteotendinous 
reflexes, normal vibratory proprioceptive sensitivity, and 
tactile, thermal and pain hypoesthesia in the lateral portion 
of the right foot. Complementary laboratory exams were 
normal (Rapid HIV I and II tests, serum VDRL, Serology 
for Hepatitis B and C, folate, vitamins B12 and D serum 
levels, complete blood count, erythrocyte sedimentation 
rate, fasting glycemia, glycated hemoglobin, oral glucose 
tolerance test, thyroid, liver and kidney functions and uri-
nalysis). While still in use of pravastatin, results of the first 
nerve conduction study (NCS) were: unexcitable right su-
ral nerve and left sural nerve with low amplitude sensory 
nerve action potential (Figure 1). The hypothesis of senso-
ry multiple mononeuropathy secondary to statin use was 
established with subsequent drug withdrawal (pravastatin) 
and clinical observation. After three months, the patient 
reported significantly improvement of the previous com-
plaints and repeat NCS (performed by the same examiner, 
with the same electroneuromyography device) disclosed 
right sural nerve with reduction in amplitude and slowing 
of sensitive conduction velocity and left sural nerve with 
slight slowing in sensitive conduction velocity (Figure 2). 
The two electromyographies performed were normal.
DISCUSSION 
In general, statins (HMG-CoA Reductase inhibi-
tors) are well tolerated and effective in reducing cerebro-
vascular and cardiovascular risk. However, although un-
common, adverse effects may occur in multiple systems, 
with involvement of the liver and skeletal musculature 
being the most serious7. The first report suggesting an as-
sociation between peripheral neuropathy (PN) and statin 
use was published in 19938. There are now numerous des-
criptions of cases and population-based studies investiga-
ting the existence of this clinical entity9. The physiopatho-
genic mechanism of PN induced by HMG-CoA inhibitors 
is based on the hypothesis related to certain biochemical 
reactions, particularly those involved in lowering sera 
cholesterol and inhibition of the synthesis of Coenzyme 
Q10 (ubiquinone). Cholesterol is essential for the process 
of nerve myelination and maintenance of the neuronal 
cell membrane and is thus important for synaptic activity. 
Coenzyme Q10 activity reduction affects mitochondrial 
function, leading to loss of the antioxidant effect which, in 
physiological conditions, is protective to neurons10. Mul-
tiple factors can influence the therapeutic response and 
chance of collateral effects secondary to statin use, such 
as genetic polymorphism, comorbidities, drug interaction, 
and particularities of the subclasses of statins1. 
In 2005, in Australia, the Adverse Drug Reactions 
Advisory Committee (ADRAC) reported having received, 
since 1993, 281 reports of polyneuropathy probably as-
sociated with statin use (the majority associated with sin-
vastatin and atorvastatin and, less frequently, pravastatin 
and fluvastatin). Many of these patients had confounding 
factors for the establishment of the etiology of PN, such as 
chronic kidney disease and diabetes. However, after sta-
tins withdrawal, recovery was seen in around 50% of these 
cases11. 
A publication of 2006 disclosed that results of an 
metanalysis involving 4 cohort-type studies3, 13, 14, 15 revea-
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led an odds ratio of 1.8 (95% CI 1.1 – 3.0; p < 0.001) for use 
of statins and risk of peripheral neuropathies (such studies 
included analysis of PN in research participants taking or 
not taking those drugs). In the same paper, authors sugges-
ted an incidence of 12 cases per 100,000 persons/year and 
a prevalence of 60 cases per 100,000 persons12. Another 
study suggested a frequency of 4.5 PN cases per 10,000 
persons/year in use of statins after excluding other predis-
posing factors3.
It has been suggested that the emergence of clini-
cal symptoms consistent with peripheral neuropathic com-
promise is directly related to the exposure time to the drug 
and also to the dose used16. This association was supported 
by 16 case reports in which PN symptoms manifested wi-
thin two months of initiating statins7,12. As cited by Henri-
ques et al. in a recent literature review, according different 
studies, the withdrawal of the drug led to improvement in 
the clinical condition in most patients where mean (par-
tial or full) recovery time was 61 days (ranging from two 
weeks to 9 months)1. In addition, an inversely proportional 
relationship between exposure time to statins and probabi-
lity of complete recovery from PN was observed in some 
cases17.
In 2011, Otruba et al. followed 42 patients (23 
men – mean age 51.9 years and 19 women – mean age 
52.3 years) with defined diagnosis of dyslipidemia and no 
history of other metabolic disorders or alcoholism. The 
study participants first underwent neurophysiological stu-
dy (fibular and tibial nerves – motor nerve conduction ve-
locity, compound muscle action potential, F wave latency; 
superficial and sural fibular nerves – sensory nerve con-
duction velocity, sensory action potential). Subsequently, 
sinvastatin 20 mg/day was prescribed and the neurophy-
siological assessment repeated at 24 and 36 months. None 
of the participants reported peripheral neuropathy-related 
complaints during the follow-up. However, NCS revealed 
prolonged F wave latency in the fibular and tibial nerves 
with a statistically significant value (p < 0.0001, paired 
Figure 1 – NCS disclosing reduced sensitive nerve conduction amplitude in left sural nerve (5,2 µV) and absent sensory nerve action potential in right 
sural nerve (Patient still in use of pravastatin 20mg/day).
Figure 2 – Sensory NCS disclosing a conduction velocity of 30,2m/s and an amplitude of 9,1µV in left sural nerve, a conduction velocity of 28,8m/s 
and amplitude of 2,5µV in right sural nerve (three months after withdrawal of pravastatin).
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t-test). The study concluded that long-term statin use may 
cause clinically silent damage to peripheral nerves when 
treatment time exceeds two years18.
Statin-induced PN typically presents as motor-sen-
sitive polyneuropathy with insidious onset19 and clinical 
symptoms range from paresthesias, hypo or hyperesthesia 
of the extremities, hypo or areflexia, motor deficit and dy-
sautonomia1, 12, 18. Some more atypical cases possibly asso-
ciated with treatment using statins have also been reported, 
characterized by neurological changes resembling Gui-
llain-Barré Syndrome20, reversible small fiber neuropathy3 
and mononeuropathy multiplex21, 22. Regarding treatment, 
when statin-induced PN is suspected, withdrawal of this 
class of drug should be considered. 
Some authors defend the use of ubiquinone for the 
management of complications secondary to statin treat-
ment23,24. A prospective study suggested benefits of this 
enzyme (mean daily dose of 240mg/day) for the various 
adverse effects induced by HMG-CoA reductase inhibi-
tors, including those related to peripheral neuropathy25. 
However, there are few specific studies with high levels of 
evidence on the use of ubiquinone in the clinical manage-
ment of statin-induced PN. 
We reported the case of an adult middle-aged pa-
tient who presented with subacute onset of sensory chan-
ges restricted to lower limbs and no reports of other sys-
temic complaints. The exclusion of more common causes 
of peripheral neuropathy allied with evident clinical and 
electrophysiological improvement following pravastatin 
withdrawal leaded us to the most likely hypothesis of sta-
tin-induced PN. We believe that the possibility of evalua-
tion bias between the two NCS was reduced by the fact 
that these complementary exams were performed by the 
same neurophysiologist, who used the same electroneu-
romyography device.
Physician should be aware that suspicion for com-
plications associated with the use of HMG CoA-Reductase 
inhibitors is always valid, given that this drug class is wi-
dely prescribed in clinical practice.
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